Regulatory Roundup: FDA Released Draft Guidance for Industry on Safety Labeling Changes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Released Draft Guidance for Industry on Safety Labeling Changes

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA released a draft guidance for industry on Safety Labeling Changes—Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act, on April 12. The draft guidance aims to put into practice requirements and enforcement tools called for by the 2007 FDA Amendments Act (FDAAA). Specifically, the Act authorizes FDA to require (or in some cases, order) certain drug and biological product application holders to make safety related labeling changes based upon new safety information that becomes available after approval of the product.  The document applies to prescription drugs approved via NDA or ANDA and biological drugs approved via BLA.

Past practice involved the agency asking drug sponsors of approved products to make labeling changes related to safety after approval to address serious risks. The change was usually submitted in a supplement by the drug sponsor to FDA. The agency had little authority to enforce the changes, however, and negotiations between the drug sponsor and the agency were often needed, according to the draft guidance document.  Now, under FDAAA, the agency can take action against a drug sponsor if requested labeling changes are not made. Enforcement actions include initiating proceedings to withdraw approval of the drug and notifying the public about safety information. The draft guidance details the definition of “new safety information,” timeframes, and other components of such a labeling change. Comments are due by July 12, 2011.

FDA Commissioner Margaret Hamburg will testify before the US House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, on "Import Safety: Status of FDA's Screening Efforts at the Border" and Predictive Risk-based Evaluation for Dynamic import Compliance Targeting, on April 13.

FDA Center for Devices and Radiological Health Director Jeffrey Shuren is scheduled to testify before the US House Committee on Oversight & Government Reform, Subcommittee on Health Care, on the "Pathway to FDA Medical Device Approval: Is There a Better Way?" on April 14.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here